Endurance RP Limited

壽康集團有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

Deep Longevity published and granted the first microbiomic aging clock patent

The board (the "**Board**") of directors (the "**Directors**", each a "**Director**") of Endurance RP Limited (the "**Company**") wishes to inform the shareholders of the Company and potential investors of the following update in respect of Deep Longevity, Inc ("**Deep Longevity**"), a wholly-owned subsidiary of the Company.

Hong Kong-based artificial intelligence ("**AI**") innovator, Deep Longevity has been granted a patent issued by the United States Patent and Trademark Office ("**USPTO"**) covering the applications of microflora profiles in the anti-aging industry: *"Aging markers of human microbiome and microbiomic aging clock"*.

This landmark invention was originally published in Cell as a research article: "Human Gut Microbiome Aging Clock Based on Taxonomic Profiling and Deep Learning" in 2020. This article described a neural network that can estimate the age of a person based on their gut flora composition. Deep Longevity's scientists identified bacteria that could slow down or speed up the basic aging processes and thereby affect the longevity (lifespan) of a person. The article also displayed diabetes as an aging-related disease that promotes the aging of the gut community.

Deep Longevity filed the USPTO application and converted it to an international patent application in 2019. The granted patent includes claims on inventions that measure the pace of aging based on the gut community composition. More specific applications of this technology described among the claims include: altering the gut flora in a way that rejuvenates the host, AI-generated reports on the pace of aging, digital apps, personalized anti-aging diet plans and probiotics. The issued patent strategically guarantees that Deep Longevity holds priority over any anti-aging applications based on gut community profiling and ensures that Deep Longevity will be the leader in this field.

Deep Longevity is planning to commercialise products based on its microbiomic aging clock in 2023.

Deep Longevity is a pioneer in the field of biogerontology, developing anti-aging analytic software based on AI algorithms. Deep Longevity holds several patents on the applications of deep learning in anti-aging research, including the applications of digital aging models for drug design. Deep Longevity has previously published peer-reviewed research studies on such models based on epigenetic data, clinical blood tests, psychological surveys, facial images, gene expression data, and gut community composition. Earlier this month, Deep Longevity released a new web-service "FuturSelf" that features a psychological aging clock and a recommendation engine aimed at maximizing users' mental health and well-being. Consumers and employers have dramatically increased their demand for virtual mental health programs, which will continue into 2022 and beyond, with the total addressable market in the United States alone estimated at US$89 billion. It is the objective of Deep Longevity to access this market through FuturSelf by providing a much-needed virtual mental health and wellbeing offering to both employers and employees.

Deep Longevity is wholly owned by the Company, develops explainable AI systems to track the rate of aging at molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, which enables physicians to make better decisions about interventions that may slow down or reverse the aging processes. Deep Longevity developed the Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age.

Originally incubated by Insilico Medicine, Deep Longevity began its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and AI: ETP Ventures; the Human Longevity and Performance Impact Venture Fund; BOLD Capital Partners; Longevity Vision Fund; LongeVC; Michael Antonov, the co-founder of Oculus; and other expert AI and biotechnology investors. Deep Longevity established a research partnership with Human Longevity, Inc., one of the most prominent longevity organizations to provide a range of aging clocks to a network of advanced physicians and researchers.

Please refer to further details of Deep Longevity at its company website (https://www.deeplongevity.com).

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Endurance RP Limited
Jamie Gibson
Executive Director

Hong Kong, 6 July 2022

As at the date of this announcement, the Board comprises six Directors**:**

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
David Comba
Julie Oates
Mark Searle

* For identification purposes only